SAR441255, derived from the exendin-4 sequence, this synthetic peptide exhibits strong agonist activity at GLP-1, GCG, and GIP receptors
7 Semaglutide 2.4 mg, a glucagon-like peptide-1 receptor agonist, has demonstrated superior efficacy in weight reduction and cardiovascular risk mitigation in the global phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program
These broader health effects are often more meaningful than the number on a scale alone
Without proper guidance, taking supplements unnecessarily may not be beneficial
After reaching your goal weight, your prescriber will help you decide whether to continue on Wegovy to maintain your results, step down to a lower dose, or come off the medication while focusing on the habits youve built